In the study, the company will assess tolerability, safety and phamacokinetics of BAL101553 to determine the dose and administration schedule for Phase II trials.
Previosly, BAL101553, a novel microtubule-targeting agent, has showed anti-cancer activity in many drug-resistant tumor models.
Basilea CEO Anthony Man said BAL101553 is a novel small-molecule drug active against a well-validated cancer cell target and showing broad anti- tumor activity in preclinical models.